Last updated: May 26, 2026
Carvedilol Phosphate Suppliers: Who Manufactures It, Who Supplies It to Drugmakers, and What to Source (API vs Finished Dosage)?
Carvedilol phosphate is supplied through the drug supply chain in two distinct ways: (1) as an active pharmaceutical ingredient (API) used to manufacture carvedilol-containing tablets/capsules, and (2) as intermediates or branded/authorized supply of finished dose products. Public supplier identification depends on whether the target is API manufacture, DMF-holding supply, or contract manufacturing of finished dosage, and whether the market is US (FDA) or ex-US.
What suppliers provide carvedilol phosphate API (active pharmaceutical ingredient)?
Carvedilol phosphate API supply is typically concentrated among API manufacturers that hold Drug Master Files (DMFs) or that are registered and inspected for API production. In practice, “suppliers” can mean one or more of the following:
- API manufacturers: produce carvedilol phosphate API under GMP and supply to branded or generic solid-dose manufacturers.
- GMP exporters and distributors: buy API from manufacturers and resell under commercial distribution agreements.
- Contract API manufacturers (CRO/CDMO for API): run synthesis and crystallization on behalf of a brand or a generic sponsor.
- Finished-dose manufacturers: source API and sell tablets/capsules, so their procurement lists act as an indirect “supplier” channel for the API.
API quality signals procurement teams actually use
- DMF availability (US): suppliers with active DMFs can ease regulatory submissions.
- US FDA inspection history: affects supply continuity for vetted buyers.
- Particle size and polymorph control: carvedilol salt form requires consistent physicochemical properties.
- Solvent residue and heavy metal specs: critical for generic approvals and batch release.
Which companies supply carvedilol phosphate for tablets and capsules?
Most “market suppliers” for carvedilol phosphate in the US are better described as finished-dose manufacturers (tablets or capsules), because procurement decisions for a finished product often track to the tablet/capsule NDA/ANDA holder and its manufacturing sites, not a standalone “salt” label.
Carvedilol is marketed primarily as carvedilol and in salt forms in some jurisdictions; carvedilol phosphate appears in certain formulations and product specifications. When a buyer sources for dosage manufacturing, they typically qualify suppliers through:
- CoA and analytical method package
- GMP certificates
- compliance with ICH Q3D, ICH Q3C, and relevant ICH salt form control expectations
- batch traceability and stability support
Who are the leading carvedilol phosphate API manufacturers globally?
Without specific sourcing geography, the supplier set changes materially. For global supply, procurement usually targets:
- large-scale API producers with broad solid-dose portfolios
- Indian and Chinese API manufacturers with DMF pipelines into US/EU
- specialty salt-form manufacturers that can control crystallization and form consistency
In carvedilol-adjacent API categories, supplier maps often overlap with generic cardiovascular API producers. However, exact identification of “carvedilol phosphate” specifically (not carvedilol base) requires tying each vendor to:
- a DMF that explicitly lists carvedilol phosphate, or
- an inspection and manufacturing authorization that explicitly covers the phosphate API, or
- a finish-dose ANDA that lists carvedilol phosphate as the API substance in its formulation
How do you find the real carvedilol phosphate suppliers for a US ANDA/NDA?
If the end use is a US ANDA or NDA, the clean procurement route is to back into suppliers through regulatory artifacts:
- Orange Book (US): identify the carvedilol product/ANDA and the strengths.
- FDA labels and approval packages: identify the manufacturing description and sites (drug substance and drug product where shown).
- DMF holders: match drug substance references to carvedilol phosphate DMFs.
- Supplier qualification: confirm the carvedilol phosphate form, polymorph, and specs via CoA and method validation.
This approach typically identifies the specific drug substance supplier(s) more reliably than generic procurement directories, which often list “carvedilol” rather than the phosphate salt.
What is the difference between carvedilol phosphate vs carvedilol base supply?
Salt form affects:
- solubility and dissolution rate: can change bioavailability and formulation behavior
- manufacturing crystallization control: affects yield and batch-to-batch consistency
- regulatory listing: submissions can refer to different chemical entities (carvedilol base vs carvedilol phosphate), which changes who can credibly supply each.
For a buyer, the practical distinction is whether the product specification requires “carvedilol phosphate” specifically. If yes, a supplier must meet the salt-form identity, not just carvedilol free base.
What manufacturing constraints drive carvedilol phosphate sourcing risk?
Carvedilol phosphate procurement risk usually comes from:
- salt-form reproducibility: changing crystallization parameters can shift form or impurity profile
- API impurity profile stability: vendors must show consistent impurity control across scale-ups
- cross-site batch transfer: if the supplier uses multiple sites, the buyer needs full tech transfer and validation support
- regulatory inspection outcomes: site issues can immediately freeze supply lines
Can contract development and manufacturing (CDMO) supply carvedilol phosphate?
Yes, CDMOs generally operate in two ways:
- they manufacture finished tablets/capsules and specify the API they purchase internally (buyer deals with the CDMO, not the upstream API manufacturer)
- they run API synthesis and salt formation on behalf of the sponsor (buyer deals with the CDMO as the “supplier” for API)
For procurement, the buyer still needs:
- clear statement of whether the CDMO supplies API directly as drug substance
- the exact identity used in the registration package
- GMP compliance for the drug substance manufacturing step that yields carvedilol phosphate
What should procurement teams require from carvedilol phosphate suppliers?
A standard vendor qualification packet for carvedilol phosphate should include:
- Certificate of Analysis with identity, assay, related substances, residual solvents, and heavy metals
- GMP certificate for API manufacturing
- COA trend reports across multiple lots (not only one-off release)
- impurity specification framework and analytical method summaries
- stability data or stability commitment for the salt form
- audit report summary or audit letter for critical suppliers
- documentation supporting consistent polymorph/form and salt identity tests
What is the fastest route to shortlist carvedilol phosphate suppliers?
The fastest route usually follows a regulatory linkage:
- identify the ANDA/NDA product that uses carvedilol phosphate (if specified)
- retrieve manufacturing site information and drug substance references
- narrow to DMF holders and then verify GMP status and salt-form capability
This avoids list-based errors where a supplier sells carvedilol (base) but not the phosphate salt.
Key Takeaways
- “Carvedilol phosphate suppliers” splits into two procurement realities: API suppliers and finished-dose manufacturers.
- Accurate supplier identification requires tying the phosphate salt requirement to US Orange Book/ANDA information and/or DMF listings.
- The key qualification risk is salt-form control and impurity consistency, not only general carvedilol manufacturing capability.
- The most reliable supplier shortlist is built from regulatory references (DMF and manufacturing sites), then validated through GMP and CoA packages.
FAQs
1) How can I verify whether a vendor supplies carvedilol phosphate or only carvedilol base?
Request CoA for identity tests that explicitly confirm “carvedilol phosphate,” plus regulatory/DMF documentation referencing the salt form.
2) Do carvedilol phosphate suppliers need a DMF for US market supply?
Many do, but procurement should treat DMF reference as a practical qualifier for regulatory submission readiness, especially for US ANDAs.
3) What documents matter most when qualifying carvedilol phosphate API suppliers?
GMP certificate, DMF reference or regulatory correspondence, full CoA with impurity/residual solvent/heavy metal data, and salt-form/polymorph identity method evidence.
4) Can the same supplier provide both carvedilol phosphate and finished carvedilol tablets?
Yes in many cases, but verify the chain of control and whether the tablet drug product uses carvedilol phosphate as the specified API substance.
5) What drives batch failures or supply interruptions for carvedilol phosphate?
Salt-form reproducibility, crystallization variability, and shifts in impurity profiles across manufacturing sites or scale changes.
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. Drug Master Files (DMF). U.S. Food and Drug Administration.
- EMA. ICH Q3A/Q3B/Q3C/Q3D and solid form guidance materials. European Medicines Agency.
